doi:10.3969/j.issn.1004-583X.2022.02.014

Abstract

CLC Number:

R521
R587.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.02.014

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I2/166

References 32

[1]	Soh AZ, Chee CB, Wang YT, et al. Dietary cholesterol increases the risk whereas pufas reduce the risk of active tuberculosis in Singapore Chinese[J]. J Nutr, 2016,146(5):1093-1100. doi: 10.3945/jn.115.228049 URL
[2]	Lai CC, Lee MT, Lee SH, et al. Statin treatment is associated with a decreased risk of active tuberculosis: An analysis of a nationally representative cohort[J]. Thorax, 2016,71(7):646-651. doi: 10.1136/thoraxjnl-2015-207052 URL
[3]	Magee MJ, Salindri AD, Kornfeld H, et al. Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins[J]. Eur Respir J, 2019,53(3):1801695. doi: 10.1183/13993003.01695-2018 URL
[4]	Dutta NK, Bruiners N, Pinn ML, et al. Statin adjunctive therapy shortens the duration of TB treatment in mice[J]. J Antimicrob Chemother, 2016,71(6):1570-1577. doi: 10.1093/jac/dkw014 URL
[5]	Guerra-De-Blas PDC, Bobadilla-Del-Valle M, Sada-Ovalle I, et al. Simvastatin enhances the immune response against mycobacterium tuberculosis[J]. Front Microbiol, 2019,10:2097. doi: 10.3389/fmicb.2019.02097 pmid: 31616387
[6]	Krishnan N, Robertson BD, Thwaites G. Pathways of IL-1β secretion by macrophages infected with clinical mycobacterium tuberculosis strains[J]. Tuberculosis (Edinb), 2013,93(5):538-547. doi: 10.1016/j.tube.2013.05.002 URL
[7]	Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity[J]. Nat Rev Immunol, 2003,3(2):133-146. doi: 10.1038/nri1001 pmid: 12563297
[8]	Khader SA, Partida-Sanchez S, Bell G, et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after mycobacterium tuberculosis infection[J]. J Exp Med, 2006,203(7):1805-1815. doi: 10.1084/jem.20052545 URL
[9]	Parihar SP, Guler R, Khutlang R, et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation[J]. J Infect Dis, 2014,209(5):754-763. doi: 10.1093/infdis/jit550 pmid: 24133190
[10]	Bruiners N, Dutta NK, Guerrini V, et al. The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis[J]. J Lipid Res, 2020,61(12):1617-1628. doi: 10.1194/jlr.RA120000895 pmid: 32848049
[11]	Rodríguez-Perea AL, Montoya CJ, Olek S, et al. Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals[J]. J Immunol Res, 2015,2015:762506. doi: 10.1155/2015/762506 pmid: 25759848
[12]	Masadeh M, Mhaidat N, Alzoubi K, et al. Antibacterial activity of statins: A comparative study of atorvastatin, simvastatin, and rosuvastatin[J]. Ann Clin Microbiol Antimicrob, 2012,11:13. doi: 10.1186/1476-0711-11-13 URL
[13]	Miyata R, Bai N, Vincent R, et al. Statins reduce ambient particulate matter-induced lung inflammation by promoting the clearance of particulate matter, <10 μm from lung tissues[J]. Chest, 2013,143(2):452-460. doi: 10.1378/chest.12-1237 URL
[14]	Gatfield J, Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages[J]. Science, 2000,288(5471):1647-1650. pmid: 10834844
[15]	Pieters J. Entry and survival of pathogenic mycobacteria in macrophages[J]. Microbes Infect, 2001,3(3):249-255. pmid: 11358719
[16]	Kim MJ, Wainwright HC, Locketz M, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism[J]. EMBO Mol Med, 2010,2(7):258-274. doi: 10.1002/emmm.v2:7 URL
[17]	Appelberg R. Macrophage nutriprive antimicrobial mechanisms[J]. J Leukoc Biol, 2006,79(6):1117-1128. doi: 10.1189/jlb.0206079 URL
[18]	Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol[J]. Proc Natl Acad Sci U S A, 2008,105(11):4376-4380. doi: 10.1073/pnas.0711159105 pmid: 18334639
[19]	Loike JD, Shabtai DY, Neuhut R, et al. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol[J]. Arterioscler Thromb Vasc Biol, 2004,24(11):2051-2056. pmid: 15345508
[20]	Su VY, Su WJ, Yen YF, et al. Statin use is associated with a lower risk of TB[J]. Chest, 2017,152(3):598-606. doi: 10.1016/j.chest.2017.04.170 URL
[21]	Liao KF, Lin CL, Lai SW. Population-based case-control study assessing the association between statins use and pulmonary tuberculosis in Taiwan[J]. Front Pharmacol, 2017,8:597. doi: 10.3389/fphar.2017.00597 URL
[22]	Li X, Sheng L, Lou L. Statin use may be associated with reduced active tuberculosis infection: A Meta-analysis of observational studies[J]. Front Med (Lausanne), 2020,7:121.
[23]	Lee MY, Lin KD, Hsu WH, et al. Statin, calcium channel blocker and Beta blocker therapy may decrease the incidence of tuberculosis infection in elderly Taiwanese patients with type 2 diabetes[J]. Int J Mol Sci, 2015,16(5):11369-1184. doi: 10.3390/ijms160511369 URL
[24]	Pan SW, Yen YF, Feng JY, et al. Opposite effects of statins on the risk of tuberculosis and herpes zoster in patients with diabetes: A population-based cohort study[J]. Br J Clin Pharmacol, 2020,86(3):569-579. doi: 10.1111/bcp.v86.3 URL
[25]	Kang YA, Choi NK, Seong JM, et al. The effects of statin use on the development of tuberculosis among patients with diabetes mellitus[J]. Int J Tuberc Lung Dis, 2014,18(6):717-724. doi: 10.5588/ijtld.13.0854 pmid: 24903944
[26]	Kim MC, Yun SC, Lee SO, et al. Association between tuberculosis, statin use, and diabetes: A propensity score-matched analysis[J]. Am J Trop Med Hyg, 2019,101(2):350-356. doi: 10.4269/ajtmh.18-0983 URL
[27]	Skerry C, Pinn ML, Bruiners N, et al. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen[J]. J Antimicrob Chemother, 2014,69(9):2453-2457. doi: 10.1093/jac/dku166 URL
[28]	Lobato LS, Rosa PS, Ferreira Jda S, et al. Statins increase rifampin mycobactericidal effect[J]. Antimicrob Agents Chemother, 2014,58(10):5766-5774. doi: 10.1128/AAC.01826-13 pmid: 25049257
[29]	Gu W, Cui R, Ding T, et al. Simvastatin alleviates airway inflammation and remodelling through up-regulation of autophagy in mouse models of asthma[J]. Respirology, 2017,22(3):533-541. doi: 10.1111/resp.2017.22.issue-3 URL
[30]	Wang JY, Yao TC, Tsai YT, et al. Increased dose and duration of statin use is associated with decreased asthma-related emergency department visits and hospitalizations[J]. J Allergy Clin Immunol Pract, 2018, 6(5):1588-1595.e1. doi: 10.1016/j.jaip.2017.12.017 URL
[31]	Neukamm A, Høiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): A randomized controlled trial[J]. J Intern Med, 2015,278(1):59-67. doi: 10.1111/joim.12337 pmid: 25495178
[32]	Wu WT, Chen CY. Protective effect of statins on pulmonary hypertension in chronic obstructive pulmonary disease patients: A nationwide retrospective, matched cohort study[J]. Sci Rep, 2020,10(1):3104. doi: 10.1038/s41598-020-59828-0 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 32

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Lei, Li Mingwu, Wan Rong. Diagnostic value of laboratory indexes in patients with pulmonary tuberculosis complicated by pulmonary embolism [J]. Clinical Focus, 2024, 39(2): 134-139.
[2]	. [J]. Clinical Focus, 2023, 38(8): 737-742.
[3]	Wolazihan Madeniyati, Dilixiati Tuerdimaimaiti, Li Mengchen, Baihetinisha Tuerdi. Meta-analysis of the application value of metagenomic next-generation sequencing technology in the diagnosis of pulmonary tuberculosis [J]. Clinical Focus, 2023, 38(5): 389-398.
[4]	Xu Jingran, Li Feifei, Xie Chengxin, Gong Hui, Luan Qiyun, Li Li. Application of endobronchial ultrasound transbronchial lung biopsy with guide sheath and rapid on-site evaluation in the diagnosis of bacteriologically-negative pulmonary tuberculosis [J]. Clinical Focus, 2022, 37(3): 220-224.
[5]	Li Baiyuan, Li Yuanjun, Li Lingxia. Study of mobile phone dependence and sleep disorder in patients with pulmonary tuberculosis [J]. Clinical Focus, 2021, 36(8): 719-723.
[6]	Lu Haoyang, Lu Jiazhong, Han Mingfeng, Lvh Xincai, Zhang Biao, Rong Chengzhen, Jia Leilei, Pan Qiangqiang, Ma Leilei, Zhao Ren. Observations on clinical treatment of COVID-19 complicated with cardiovascular disease [J]. Clinical Focus, 2021, 36(3): 203-207.
[7]	. [J]. Clinical Focus, 2015, 30(12): 1427-1428.
[8]	Lu Qingyun;Chen Wufei. Feasibility analysis of ultra low dose CT in follow-up physical examination population with solid pulmonary nodules [J]. Clinical Focus, 2015, 30(6): 637-640.
[9]	. [J]. Clinical Focus, 2015, 30(2): 214-216.
[10]	MENG Wei-li;ZHU Dan-hong;LI Qing;XU Jun;LI Zhen;ZOU Ze-yang;SUN Zhao;HU Jing-kun;LANG Ying;LIAN He-yu. Value of serum adenosine deaminase in diagnosis and treatment of smear negative pulmonary tuberculosis [J]. Clinical Focus, 2014, 29(11): 1228-1232.
[11]	REN Jin-jun;ZHAO Bao-hong;YU Zhe;ZHANG Yu-huan;ZI Xue-rong;XU Qian;CHEN Yan-fang. Evaluation of solitary pulmonary nodule by diffusion-weighted MR imaging [J]. Clinical Focus, 2014, 29(11): 1265-1267.
[12]	. [J]. Clinical Focus, 2014, 29(7): 797-799.
[13]	ZHANG Ling. New thinking in pulmonary tuberculosis diagnosis and drug-resistant tuberculosis treatment [J]. Clinical Focus, 2014, 29(6): 601-604.
[14]	WANG Li-wei;WANG Zi-zhen. Clinical effect of application of chemotherapy regimens in multiple drug resistant tuberculosis patients [J]. Clinical Focus, 2014, 29(6): 605-607.
[15]	BAI Guang-hong;ZHU Lei;GAO Man. Clinical application of seven experimental methods in tuberculosis diagnosis [J]. Clinical Focus, 2014, 29(6): 608-610611.